Valuation
- Market cap
- 266,150,000
- Revenue TTM
- $37,860,000
- Net income TTM
- $-57,250,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -151.22%
- Debt to equity
- 0.00
Trading
- Volume
- 1,158,100
- Avg volume
- 1,649,014
- Day's range
- $4.99 – $5.01
- Shares out
- 53,230,000
- Stochastic %K
- 67%
- Beta
- 1.04
- Analysts
- Hold
- Price target
- $5.50
Company profile
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. 2seventy bio, Inc. was incorporated in 2021 and...
Show more
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. 2seventy bio, Inc. was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 617 675 7270
- Website
- https://www.2seventybio.com
- Address
- 60 Binney Street, Cambridge, United States
Latest news
No headlines yet.
